Patient demographics and baseline characteristics
| Cohort* | Total (n=65) | ||
| Anetumab ravtansine 5.5 mg/kg plus pegylated liposomal doxorubicin 30 mg/m2 (n=3) | Anetumab ravtansine 6.5 mg/kg plus pegylated liposomal doxorubicin 30 mg/m2 (n=62) | ||
| Age | |||
| Median, years (range) | 55 (51–65) | 63 (42–80) | 63 (42–80) |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 0 | 3 (4.8) | 3 (4.6) |
| Non-Hispanic or non-Latino | 3 (100) | 59 (95.2) | 62 (95.4) |
| Eastern Cooperative Oncology Group performance status at baseline, n (%) | |||
| 0 | 2 (66.7) | 35 (56.5) | 37 (56.9) |
| 1 | 1 (33.3) | 27 (43.5) | 28 (43.1) |
| Time since diagnosis | |||
| Median (range), days | 806.0 (261–1875) | 1066.0 (181–5561) | 1064.0 (181–5561) |
| Time since most recent progression | |||
| Median (range), days | 34.0 (30–89) | 32.5 (8–247) | 33.0 (8–247) |
| Primary location of cancer at initial diagnosis, n (%) | |||
| Fallopian tube | 0 | 5 (8.1) | 5 (7.7) |
| Ovary | 3 (100) | 54 (87.1) | 57 (87.7) |
| Peritoneum | 0 | 3 (4.8) | 3 (4.6) |
| FIGO stage, n (%) | |||
| IC | 0 | 1 (1.6) | 1 (1.5) |
| IIB | 0 | 3 (4.8) | 3 (4.6) |
| IIIB | 0 | 2 (3.2) | 2 (3.1) |
| IIIC | 3 (100) | 31 (50.0) | 34 (52.3) |
| IV | 0 | 25 (40.3) | 25 (38.5) |
| Prior systemic therapies, median (IQR and range), n (%) | 3 (1–5 and 1–5) | 4 (2–5 and 1–10) | 4 (2–5 and 1–10) |
| 1–≤3 | 2 (66.6) | 29 (46.8) | 31 (47.7) |
| 4–≤6 | 1 (33.3) | 24 (38.7) | 25 (38.4) |
| >6 | 0 | 9 (14.5) | 9 (13.8) |
| Most common prior systemic therapies, n (%) | |||
| Platinum compounds | 65 (100) | ||
| Taxanes | 57 (87.7) | ||
| Doxorubicin compounds | 41 (63.1) | ||
| Bevacizumab | 33 (50.8) | ||
| PARP inhibitor | 14 (21.5) | ||
| Antibody drug conjugates with DM4 payload | 7 (10.8) | ||
| Immune checkpoint inhibitors | 6 (9.2) | ||
*All cohorts received anetumab ravtansine every 3 weeks in combination with pegylated liposomal doxorubicin.